Black cohosh (Cimicifuga racemosa) is a plant native to the eastern United States and Canada, originally used by Native Americans as a remedy for menstrual and menopausal symptoms, among other conditions. In Europe, black cohosh root extract has had widespread use for more than half a century for menopausal symptoms (Liske, 1998) and is marketed in Germany as Remifemin ® (Schaper & Brummer GmbH & Co. KG, Salzgitter, Germany) . Black cohosh is unrelated to blue cohosh or white cohosh.
Route of administration: Black cohosh is taken orally as a capsule, fl uid extract, tablet, powder, or tincture. Dosing and cost: A variety of factors infl uence the dosing of black cohosh, such as growing and harvesting conditions, plant parts and extraction methods, and dosage forms selected by manufacturers. Most clinical studies use a specifi c black cohosh extract standardized to contain 1 mg triterpene glycosides (calculated in the key marker 27-deoxyacetin) per 20 mg tablet with a total dose of 40-80 mg twice daily. An aqueous extract of black cohosh with dosages of 39 mg and 127.3 mg also has been used (Natural Medicines Comprehensive Database, 2005; Thomson™ Micromedex, 2005) . At a dose of 20 mg twice daily of standardized black cohosh, the monthly cost is approximately $15, which is not covered by most prescription plans.
Indications: Black cohosh is marketed commercially as an alternative to hormonal therapy in the relief of symptoms associated with menopause, premenstrual syndrome, and dysmenorrhea.
Regulation: As a dietary supplement as defi ned by the Dietary Supplemental Health and Education Act of 1994, black cohosh does not fall under postmarket regulation by the U.S. Food and Drug Administration (FDA). The FDA is responsible, however, for taking action against any unsafe products once reported.
Safety and effi cacy: The pharmacokinetic profi le of black cohosh has yet to be 
